Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Sales Volume & ASP by Product Type & End-User The global cell counting market will witness a robust CAGR of 7%, valued at $10.48 billion in 2021, expected to appreciate and reach $19.27 billion by 2030, confirms Strategic Market Research. North America leads the cell counting devices market because of the rising prevalence of chronic illnesses. Cell counting is an essential step in calculating cell concentrations for plating in culture, detecting cell viability, and evaluating the results of cell isolation processes. The purpose of cell counting is to have a close view of cell health and its growth rate. The National Cancer Institute delineated that there are likely to be 1,918,030 new cancer cases and 609,360 cancer deaths in the United States in 2022, with lung cancer being the leading cause of cancer mortality, resulting in nearly 350 fatalities each day. Before cell isolation, it is advisable to do an initial cell count; this number may then be compared to the cell count following cell isolation to assess cell recovery. Furthermore, viable cell counts should be done when a decline in cell viability is predicted, such as when working with cryopreserved cells or ex vivo modified cells. In life science, cell counting methods such as hemocytometer (counting chamber), electrical resistance, and automated cell counting (electronic cell counting) are the most accurate ways to count cells. The rising incidence of chronic illnesses and rising technical advancements and product releases in the cell counting market globally are likely to propel the industry forward. Market Drivers - Increasing Occurrence of Target Illnesses, Technological Advancement, and Higher Adoption Rate The global cell counting market is primarily driven by the increased occurrence of target illnesses such as HIV, measles, diphtheria and chronic diseases like cancer, haemophilia and some other blood disorders. The World Health Organization says that close to 37.7 million people worldwide will be suffering from HIV by the end of 2020. Furthermore, 680,000 people died from HIV-related causes in 2020, while 1.5 million people are likely to catch the infection in the upcoming years. According to National Haemophilia Foundation, close to 33,000 people with haemophilia live in the U.S., out of which 60% of the cases are severe. As a result, growing infectious illness cases are likely to drive the significant growth of the cell counting industry. Furthermore, technical developments in cell counting equipment or reagents have resulted in more product introductions, thus propelling the market growth. For example, The CellDrop, an automated cell counter by DeNovix Inc, which allows scientists to count cells without slides, was given the prestigious Best New Life Science Product of the Year Award on 19th May 2020. Also, a higher rate of adoption of the devices like b cell markers to perform b cell count test that counts cells in interphase, cell counting microscopes and image analysis software like stereological cell counting in imagej, cell counting in fiji that gives an exact cell counting and viability (through plating and CFU counting) of blood cells are also significantly driving the growth of the market. Market Restraints - Lack of Awareness, High Cost of Technologies, and Lack of Professionals The Global Cell Counting market's growth is hampered by the high cost of sophisticated cell counting technologies, the lack of experienced professionals, and haematology analyzer product recalls. Opportunities - Increasing Incidence of Blood-Related Issues, Rising Number of Collaborations, and Increasing Government Support Government measures encouraging the growth of cell therapies, in which cell counting plays a critical part, are boosting the market's growth prospects for the future. Europe is the global leader in cell and gene therapy (CGT) research since it is home to sixteen of the top 50 global life science universities. According to one McKinsey survey, the European Union would invest around EUR 7 billion in health research between 2021 and 2027 as part of the Horizon Europe initiative. Moreover, in the Fiscal Year 2020, the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) delivered HIV testing to almost 50 million individuals and funded lifesaving ART for approximately 18.2 million men, women, and children. Furthermore, the increased incidence of chronic blood-related illnesses is likely to add to the expansion of this market. According to one study in 2020, the incidence rate of leukaemia globally is 274,519, with 311,594 deaths due to the disease. Because of these disorders' high prevalence and fatality, the rate of adoption will increase, thus resulting inadequate market growth in the future. The cell counting market has benefited from collaborations between research institutes and various organizations to enhance R&D activities in the upcoming years. U.S. Food & Drug Administration (FDA) now has over 800 active cell-based or directly administered gene therapy investigational new medicines (INDs) on file. By 2025, the FDA intends to approve 10 to 20 cell and gene therapy products each year, based on assessing the current pipeline and clinical success rates. Various microorganisms and infectious diseases destroy our immune system, reducing the t-cell counts. In a survey, the Office of Disease Prevention and Health Promotion reported that sickle cell disease is a serious blood disorder that affects more than 100,000 people in the United States every year. However, the improvement in new technologies like cell therapy that replaces the damaged blood cells and the adoption of instruments is projected to improve the market's growth in the following years. Market Analysis Of Different Segments Covered in the Report Based on Product: Instruments Spectrophotometers Flow Cytometers Haematology Analyzers Cell Counters Consumables & Accessories Reagents Microplates Others Based on End-User: Hospitals & Diagnostic Laboratories Research & Academic Institutes Pharmaceutical & Biotechnology Companies Others Regional Coverage Analysis North America The U.S. Canada Mexico Rest of North America Europe The U.K. Germany France Italy Spain Rest of Europe Asia Pacific Japan China India Rest of APAC LAMEA Brazil Argentina Saudi Arabia Rest of LAMEA Product Analysis & Insights The sectrophotometers held a significant market percentage. As a result, spectrophotometry has evolved as the primary method for quantifying cell concentration in research, medicine, and bioprocessing. The ability of these sensors to precisely monitor a wide range of light intensities has led to their growing acceptance. However, the instrument's high price is predicted to slow down the market acceptance rate in the future. End-Users Analysis & Insights The Hospitals and Diagnostic Laboratories will grow at the fastest CAGR throughout the forecasted period. The rapid growth of this category can be attributed to a rise in board approval for cell culture-based antibiotics, higher pharmaceutical R&D spending, and commercial development by various pharmaceutical companies. Furthermore, many AIDS and cancer patients depend on hospitals and diagnostic laboratories for effective treatment and evaluation due to the highly developed infrastructure facilities equipped with modern technologies. According to the Minority HIV/AIDS Fund (MHAF), in 2020, around 84 % of the people living with HIV globally knew their HIV status. The remaining 16 % (about 6.0 million people) still require HIV testing. Also, in 2020, an estimated 1.5 million people worldwide contracted HIV, representing a 31% decrease in new HIV infections since 2010. Region Analysis & Insights Based on Region, North America leads the cell counting devices market because of the rising prevalence of chronic illnesses such as heart and blood disorders. Furthermore, improved healthcare infrastructure and the expansion of government-sponsored stem cell research and development activities would propel the advancement of the cell counting devices market in this region. The National Cancer Institute estimated that there were 16.9 million cancer survivors in the United States in 2020, and by 2030, the number of cancer survivors is expected to reach 22.2 million. On the other hand, because of the prevalence of a wide range of clinical studies and biopharmaceutical businesses in the Asia Pacific, the cell counting devices market is expected to rise significantly in the region. Cell Counting Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 Market size value in 2021 USD 10.48 billion Revenue forecast in 2030 USD 19.27 billion Growth rate CAGR of 7.0 % The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Product, By End User, By Region By Product Instruments, Consumables & Accessories By End-User Hospitals & Diagnostic Laboratories, Research & Academic Institutes, Pharmaceutical & Biotechnology Companies, Others By Region Asia Pacific, North America, Europe, and LAMEA Country Scope US, Mexico, Canada, Germany, UK, France, China, Japan, India etc. Company Usability Profiles Thermo Fisher Scientific Inc, Merck KGaA, PerkinElmer Inc, Olympus Corporation, HORIBA Ltd, Logos Biosystems Inc, Corning Incorporated, Tecan Trading AG, Abbott, General Electric Company, Boule Diagnostics AB, Becton, Dickinson and Company. Pricing and purchase options Customized buying options are available to meet your exact research needs. Global Cell Counting Market Competitive Landscape Analysis The competitive landscape analysis gives an overview of some prominent players operating in the market. Product innovation and continued R&D operations to create sophisticated technologies have assisted the market's growth. In the target market, there are many significant companies, and some of the Cell Counting Market leaders are: Thermo Fisher Scientific Inc Merck KGaA PerkinElmer Inc Olympus Corporation HORIBA Ltd Logos Biosystems Inc Corning Incorporated Tecan Trading AG Abbott General Electric Company Boule Diagnostics AB Becton, Dickinson and Company Tip Biosystems Agilent Technologies Inc Sysmex Corporation Siemens Healthcare Private Limited Diconex Beckman Coulter Inc Nexcelom Bioscience LLC ChemoMetec A/S Bio-Rad Laboratories Inc Advanced Instruments R&D Systems, Inc. Cole-Parmer Instrument Company LLC Recent Developments: On March 2022, Erasmus University Medical Center (Erasmus MC) in the Netherlands signed a digital pathology contract with Sectra, an international medical imaging I.T. and cybersecurity firm. Hence, the pathologists will be able to examine and collaborate on cases in ways that are impossible to do with microscopes. It will improve cancer care in the future by reducing variance and increasing efficiency in basic diagnostics. On February 2022, for its Guava range of Flow Cytometry Instruments and Reagents, Abacus dx signed a new agreement with Luminex. Luminex has produced the most incredible variety of accessible flow cytometric analyzers because of a rich tradition and culture of innovation. These flow cytometers have unique characteristics that drive the research to another level. In June 2021, CytoSMART Technologies created one of the first fluorescent cell counters. The CytoSMART Exact FL is a highly autonomous dual fluorescence cell counter with artificial intelligence (A.I.) algorithms that provide highly reliable picture recognition. On April 2020, in collaboration with CellaVision, HORIBA UK Ltd released a new automated digital cell morphology solution to enable haematology laboratories to simplify and accelerate the performance of blood and bodily fluid differentials. HORIBA's HELO automated haematology platform may now be linked with CellaVision's digital cell morphology systems, allowing for a unique two-way data flow and quick confirmation of cell morphology results. These integrated systems automate various tasks that otherwise would have been performed by hand, resulting in greatly improved laboratory operations and increased productivity. On March 2020, Danaher Corporation completed the acquisition of the biopharma business of G.E. and named it Cytiva, which operates as a standalone company within the life science section of Danahar. Various Devices that the Market Leaders are Manufacturing Name of the Product Function Key Player Countess 3 Automated Cell Counter Brightfield cell counts are easy, rapid, and inexpensive ways to prepare cells for downstream applications for culture splits. Thermo Fisher Scientific Inc LUNA-FX7 Used for automated fluorescence and brightfield image-based cell detection Logos Biosystems Scepter3.0 Scepter 3.0 Cell Counter is a portable and handheld automated cell counter. This cell counter is the only one that brings Coulter impedance counting precision and consistency to the culture hood. While existing automated counters take up valuable bench space and rely on object recognition software, manual focusing, and clunky loading chambers, Scepter 3.0 cell counter offers complete automation without the risk of mistakes associated with vision-based systems. Merck Cellometer Spectrum An advanced, modular cell counter with the ability to execute cell-based experiments using fluorescence reagents and kits. The device can also be customized to meet the needs of individual tests or reagents. Nexcelom Frequently Asked Question About This Report What are the most dominant regions of the global market? North America leads the cell counting devices market. Because of a range of clinical studies and biopharmaceutical businesses in the Asia Pacific, the cell counting devices market is expected to rise significantly. What are the pivotal factors driving the overall growth of the global market? The growing incidence of chronic illnesses and rising technical advancements and product releases globally in the market are likely to propel the industry forward. How big is the Global Cell Counting Market size? In 2020, the Global Cell Counting Market share was USD 9.8 billion. It is predicted to reach USD 19.27 billion by 2030, with a CAGR of 7 % throughout the forecasted period. Name some of the global market players? Some of the key players are Merck KGaA, PerkinElmer Inc, Olympus Corporation, HORIBA Ltd, Logos Biosystems Inc, Corning Incorporated, Tecan Trading AG, Abbott, General Electric Company, Boule Diagnostics AB Sources https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html https://www.who.int/news-room/fact-sheets/detail/hiv-aids https://www.hemophilia.org/bleeding-disorders-a-z/types/hemophilia-a https://www.mckinsey.com/capabilities/strategy-and-corporate-finance/our-insights/securing-europes-competitiveness-addressing-its-technology-gap https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061017/ 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Cell Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Global Cell Market 4.2.1 Global market, 2021 – 2028 (USD Million) 4.3 Regional Business Analysis 4.3.1 Global market, by Region, 2021 - 2030 (USD Million) 4.4 Product Business Analysis 4.4.1 Global market, By Product, 2021 - 2030 (USD Million) 4.5 End-User Business Analysis 4.5.1 Global market, By End-User, 2021 - 2030 (USD Million) 4.6 Value Chain Analysis 4.7 Market Variable Analysis 4.7.1 Market Drivers Analysis 4.7.2 Market Restraints Analysis 4.8 Business Environment Analysis Tool 4.8.1 PEST analysis 4.8.2 Porter’s analysis 4.9 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Technology Analysis 5.11.1. Trends in Technology (2014-2021) 5.11.2. Trends in Technology (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By region, By Countries) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Cell Counting Manufacturing Sites, Area Served, Product 6.3. Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Global Market: By Product Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Instruments 7.3.1. Instruments market, 2021 - 2030 (USD Million) 7.3.1.1. Spectrophotometers market, 2021 - 2030 (USD Million) 7.3.1.2. Flow Cytometers market, 2021 - 2030 (USD Million) 7.3.1.3. Haematology Analyzers market, 2021 - 2030 (USD Million) 7.3.1.4. Cell Counters market, 2021 - 2030 (USD Million) 7.4. Consumables & Accessories 7.4.1. Consumables & Accessories market, 2021 - 2030 (USD Million) 7.4.1.1. Reagents market, 2021 - 2030 (USD Million) 7.4.1.2. Microplates market, 2021 - 2030 (USD Million) 7.4.1.3. Others market, 2021 - 2030 (USD Million) 8. Global Market: By End-User Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Hospitals & Diagnostic Laboratories 8.3.1. Hospitals & Diagnostic Laboratories market, 2021 - 2030 (USD Million) 8.4. Research & Academic Institutes 8.4.1. Research & Academic Institutes market, 2021 - 2030 (USD Million) 8.5 Pharmaceutical & Biotechnology Companies 8.5.1 Pharmaceutical & Biotechnology Companies market, 2021 - 2030 (USD Million) 8.6 Others 8.6.1 Others market, 2021 - 2030 (USD Million) 9. Global Market: Regional Outlook 9.1 North America 9.1.1. North America, By Product, 2021 - 2030 (USD Million) 9.1.4. North America, By End-User, 2021 - 2030 (USD Million) 9.1.5. North America, by Country, 2021 - 2030 (USD Million) 9.1.4.1. U.S. 9.1.4.1.1. U.S. By Product, 2021 - 2030 (USD Million) 9.1.4.2. Canada 9.1.4.2.1. Canada By Product, 2021 - 2030 (USD Million) 9.1.4.2.2. Canada By Region, 2021 - 2030 (USD Million) 9.1.4.2.3. Canada by End-Users, 2021 - 2030 (USD Million) 9.2. Europe 9.2.1. Europe By Product, 2021 - 2030 (USD Million) 9.2.2. Europe By End-User, 2021 - 2030 (USD Million) 9.2.5. Europe by country, 2021 - 2030 (USD Million) 9.2.4.1 U.K. 9.2.4.1.1. U.K. By Product, 2021 - 2030 (USD Million) 9.2.4.1.2. U.K. By End-Users, 2021 - 2030 (USD Million) 9.2.4.1.3. U.K. by Region, 2021 - 2030 (USD Million) 9.2.4.2. Germany 9.2.4.2.1. Germany By Product, 2021 - 2030 (USD Million) 9.2.4.2.2. Germany By End-User, 2021 - 2030 (USD Million) 9.2.4.2.3. Germany by Region, 2021 - 2030 (USD Million) 9.2.4.3. France 9.2.4.3.1. France By Product, 2021 - 2030 (USD Million) 9.2.4.3.2. France By Region, 2021 - 2030 (USD Million) 9.2.4.3.3. France by End-User, 2021 - 2030 (USD Million) 9.2.4.4. Rest of Europe 9.2.4.4.1. Rest of Europe By Product, 2021 - 2030 (USD Million) 9.2.4.4.2. Rest of Europe By Region, 2021 - 2030 (USD Million) 9.2.4.4.3. Rest of Europe by End-User, 2021 - 2030 (USD Million) 9.3. Asia Pacific 9.3.1. Asia Pacific By Product, 2021 - 2030 (USD Million) 9.3.2. Asia Pacific By End-User, 2021 - 2030 (USD Million) 9.3.5. Asia Pacific by country, 2021 - 2030 (USD Million) 9.3.4.1. China 9.3.4.1.1. China By Product, 2021 - 2030 (USD Million) 9.3.4.1.2. China By Region, 2021 - 2030 (USD Million) 9.3.4.1.3. China by End-User, 2021 - 2030 (USD Million) 9.3.4.2. India 9.3.4.2.1. India By Product, 2021 - 2030 (USD Million) 9.3.4.2.2. India By Region, 2021 - 2030 (USD Million) 9.3.4.2.3. India by End-User, 2021 - 2030 (USD Million) 9.3.4.3. Japan 9.3.4.3.1. Japan By Product, 2021 - 2030 (USD Million) 9.3.4.3.3. Japan by End-User, 2021 - 2030 (USD Million) 9.3.4.4. South Korea 9.3.4.4.1. South Korea By Product, 2021 - 2030 (USD Million) 9.3.4.4.3. South Korea by End-User, 2021 - 2030 (USD Million) 9.3.4.5. Rest of ASIA PACIFIC 9.3.4.5.1. Rest of ASIA PACIFIC By Product, 2021 - 2030 (USD Million) 9.3.4.5.3. Rest of ASIA PACIFIC by End-User, 2021 - 2030 (USD Million) 9.4. Latin America 9.4.1. Latin America By Product, 2021 - 2030 (USD Million) 9.4.3. Latin America by End-User, 2021 - 2030 (USD Million) 9.4.4. Latin America by country, 2021 - 2030 (USD Million) 9.4.4.1. Brazil 9.4.4.1.1. Brazil By Product, 2021 - 2030 (USD Million) 9.4.4.1.3. Brazil by End-User, 2021 - 2030 (USD Million) 9.4.4.2. Mexico 9.4.4.2.1. Mexico By Product, 2021 - 2030 (USD Million) 9.4.4.2.3. Mexico by End-User, 2021 - 2030 (USD Million) 9.4.4.3. Rest of Latin America 9.4.4.3.1. Rest of the Latin America By Product, 2021 - 2030 (USD Million) 9.4.4.3.3. Rest of the Latin America by End-User, 2021 - 2030 (USD Million) 9.5. MEA 9.5.1. MEA By Product, 2021 - 2030 (USD Million) 9.5.3. MEA by End-User, 2021 - 2030 (USD Million) 10. Competitive Landscape 10.1 Thermo Fisher Scientific Inc. 10.1.1. Company overview 10.1.2. Financial performance 10.1.3. ProductPortfolio Analysis 10.1.4. Business Strategy & Recent Development 10.2. Merck KGaA. 10.2.1. Company overview 10.2.2. Financial performance 10.2.3. Product Portfolio Analysis 10.2.4. Business Strategy & Recent Development 10.3. PerkinElmer Inc. 10.3.1. Company overview 10.3.2. Financial performance 10.3.3. Product Portfolio Analysis 10.3.4. Business Strategy & Recent Development 10.4. Olympus Corporation. 10.4.1. Company overview 10.4.2. Financial performance 10.4.3. Product Portfolio Analysis 10.4.4. Business Strategy & Recent Development 10.5. HORIBA Ltd 10.5.1. Company overview 10.5.2. Financial performance 10.5.3. Product Portfolio Analysis 10.5.4. Business Strategy & Recent Development 10.6. Logos Biosystems Inc. 10.6.1. Company overview 10.6.2. Financial performance 10.6.3. Product Portfolio Analysis 10.6.4. Business Strategy & Recent Development 10.7. Corning Incorporated. 10.7.1. Company overview 10.7.2. Financial performance 10.7.3. Product Portfolio Analysis 10.7.4. Business Strategy & Recent Development 10.8. Tecan Trading AG. 10.8.1. Company overview 10.8.2. Financial performance 10.8.3. Product Portfolio Analysis 10.8.4. Business Strategy & Recent Development 10.9. Abbott. 10.9.1. Company overview 10.9.2. Financial performance 10.9.3. Product Portfolio Analysis 10.9.4. Business Strategy & Recent Development 10.10. General Electric Company. 10.10.1. Company overview 10.10.2. Financial performance 10.10.3. Product Portfolio Analysis 10.10.4. Business Strategy & Recent Development 10.11. Boule Diagnostics AB. 10.11.1. Company overview 10.11.2. Financial performance 10.11.3. Product Portfolio Analysis 10.11.4. Business Strategy & Recent Development 10.12.Becton. 10.12.1. Company overview 10.12.2. Financial performance 10.12.3. Product Portfolio Analysis 10.12.4. Business Strategy & Recent Development 10.13. Dickinson and Company. 10.13.1. Company overview 10.13.2. Financial performance 10.13.3. Product Portfolio Analysis 10.13.4. Business Strategy & Recent Development 10.14. Tip Biosystems. 10.14.1. Company overview 10.14.2. Financial performance 10.14.3. Product Portfolio Analysis 10.14.4. Business Strategy & Recent Development 10.15. Agilent Technologies Inc. 10.15.1. Company overview 10.15.2. Financial performance 10.15.3. Product Portfolio Analysis 10.15.4. Business Strategy & Recent Development 10.16. Sysmex Corporation 10.16.1. Company overview 10.16.2. Financial performance 10.16.3. Product Portfolio Analysis 10.16.4. Business Strategy & Recent Development 10.17. Siemens Healthcare Private Limited. 10.17.1. Company overview 10.17.2. Financial performance 10.17.3. Product Portfolio Analysis 10.17.4. Business Strategy & Recent Development 10.18. Diconex. 10.18.1. Company overview 10.18.2. Financial performance 10.18.3. Product Portfolio Analysis 10.18.4. Business Strategy & Recent Development 10.19. Beckman Coulter Inc. 10.19.1. Company overview 10.19.2. Financial performance 10.19.3. Product Portfolio Analysis 10.19.4. Business Strategy & Recent Development 10.20. Nexcelom Bioscience LLC. 10.20.1. Company overview 10.20.2. Financial performance 10.20.3. Product Portfolio Analysis 10.20.4. Business Strategy & Recent Development 10.21. ChemoMetec A/S. 10.21.1. Company overview 10.21.2. Financial performance 10.21.3. Product Portfolio Analysis 10.21.4. Business Strategy & Recent Development 10.22. Bio-Rad Laboratories Inc 10.22.1. Company overview 10.22.2. Financial performance 10.22.3. Product Portfolio Analysis 10.22.4. Business Strategy & Recent Development 10.23. Advanced Instruments 10.23.1. Company overview 10.23.2. Financial performance 10.23.3. Product Portfolio Analysis 10.23.4. Business Strategy & Recent Development 10.24. R&D Systems, Inc. 10.24.1. Company overview 10.24.2. Financial performance 10.24.3. Product Portfolio Analysis 10.24.4. Business Strategy & Recent Development 10.25. Cole-Parmer Instrument Company LLC 10.25.1. Company overview 10.25.2. Financial performance 10.25.3. Product Portfolio Analysis 10.25.4. Business Strategy & Recent Development List of Tables (80 Tables) TABLE 1. By Product, 2021-2030 (USD Million) TABLE 2. FOR Instrumentsl, BY REGION, 2021-2030 (USD Million) TABLE 3. FOR Spectrophotometers, BY REGION, 2021-2030 (USD Million) TABLE 4. FOR Flow Cytometers, BY REGION, 2021-2030 (USD Million) TABLE 6. FOR Haematology Analyzers, BY REGION, 2021-2030 (USD Million) TABLE 7. FOR Cell Counters, BY REGION, 2021-2030 (USD Million) TABLE 8. FOR Consumables & Accessories, BY REGION, 2021-2030 (USD Million) TABLE 9. FOR Reagents, BY REGION, 2021-2030 (USD Million) TABLE 10. FOR Microplates, BY REGION, 2021-2030 (USD Million) TABLE 11. FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 12. BY END-USER, 2021-2030 (USD Million) TABLE 13. FOR Hospitals & Diagnostic Laboratories, BY REGION, 2021-2030 (USD Million) TABLE 14. FOR Research & Academic Institutes, BY REGION, 2021-2030 (USD Million) TABLE 15. FOR Pharmaceutical & Biotechnology Companies, BY REGION, 2021-2030 (USD Million) TABLE 16. FOR Others Companies, BY REGION, 2021-2030 (USD Million) TABLE 17. BY REGION, 2021-2030 (USD Million) TABLE 18. NORTH AMERICA BY COUNTRY, 2021-2030 (USD Million) TABLE 19. NORTH AMERICA BY End-Users, 2021-2030 (USD Million) TABLE 20. NORTH AMERICA By Product, 2021-2030 (USD Million) TABLE 21. NORTH AMERICA BY END-USER, 2021-2030 (USD Million) TABLE 22. EUROPE BY COUNTRY, 2021-2030 (USD Million) TABLE 23. EUROPE By Product, 2021-2030 (USD Million) TABLE 24. EUROPE BY END-USER, 2021-2030 (USD Million) TABLE 25. ASIA-PACIFIC BY COUNTRY, 2021-2030 (USD Million) TABLE 26. ASIA-PACIFIC By Product, 2021-2030 (USD Million) TABLE 27. ASIA-PACIFIC BY END-USER, 2021-2030 (USD Million) TABLE 28. LAMEA BY COUNTRY, 2021-2030 (USD Million) TABLE 29. LAMEA By Product, 2021-2030 (USD Million) TABLE 30. LAMEA BY END-USER, 2021-2030 (USD Million) TABLE 31. Thermo Fisher Scientific Inc: COMPANY SNAPSHOT TABLE 32. Thermo Fisher Scientific Inc: OPERATING SEGMENTS TABLE 33. Merck KGaA: COMPANY SNAPSHOT TABLE 34. Merck KGaA: OPERATING SEGMENTS TABLE 35. PerkinElmer Inc: COMPANY SNAPSHOT TABLE 36. PerkinElmer Inc: OPERATING SEGMENTS TABLE 37. Olympus Corporation: COMPANY SNAPSHOT TABLE 38. Olympus Corporation: OPERATING SEGMENTS TABLE 39. HORIBA Ltd: COMPANY SNAPSHOT TABLE 40. HORIBA Ltd: OPERATING SEGMENTS TABLE 41. Logos Biosystems Inc: COMPANY SNAPSHOT TABLE 42. Logos Biosystems Inc: OPERATING SEGMENTS TABLE 43. Corning Incorporated: COMPANY SNAPSHOT TABLE 44. Corning Incorporated: OPERATING SEGMENTS TABLE 45. Tecan Trading AG: COMPANY SNAPSHOT TABLE 46. Tecan Trading AG: OPERATING SEGMENTS TABLE 47. Abbott: COMPANY SNAPSHOT TABLE 48. Abbott: OPERATING SEGMENTS TABLE 49. General Electric Company: COMPANY SNAPSHOT TABLE 50. General Electric Company: OPERATING SEGMENTS TABLE 51. Boule Diagnostics AB: COMPANY SNAPSHOT TABLE 52. Boule Diagnostics AB: OPERATING SEGMENTS TABLE 53. Becton.: COMPANY SNAPSHOT TABLE 54. Becton.: OPERATING SEGMENTS TABLE 55. Dickinson and Company: COMPANY SNAPSHOT TABLE 56. Dickinson and Company: OPERATING SEGMENTS TABLE 57. Tip Biosystems: COMPANY SNAPSHOT TABLE 58. Tip Biosystems: OPERATING SEGMENTS TABLE 59. Agilent Technologies Inc: COMPANY SNAPSHOT TABLE 60. Agilent Technologies Inc: OPERATING SEGMENTS TABLE 61. Sysmex Corporation: COMPANY SNAPSHOT TABLE 62. Sysmex Corporation: OPERATING SEGMENTS TABLE 63. Siemens Healthcare Private Limited: COMPANY SNAPSHOT TABLE 64. Siemens Healthcare Private Limited: OPERATING SEGMENTS TABLE 65. Diconex: COMPANY SNAPSHOT TABLE 66. Diconex: OPERATING SEGMENTS TABLE 67. Beckman Coulter Inc: COMPANY SNAPSHOT TABLE 68. Beckman Coulter Inc: OPERATING SEGMENTS TABLE 69. Nexcelom Bioscience LLC: COMPANY SNAPSHOT TABLE 70. Nexcelom Bioscience LLC: OPERATING SEGMENTS TABLE 71. ChemoMetec A/S: COMPANY SNAPSHOT TABLE 72. ChemoMetec A/S: OPERATING SEGMENTS TABLE 73. Bio-Rad Laboratories Inc: COMPANY SNAPSHOT TABLE 74. Bio-Rad Laboratories Inc: OPERATING SEGMENTS TABLE 75. Advanced Instruments: COMPANY SNAPSHOT TABLE 76. Advanced Instruments: OPERATING SEGMENTS TABLE 77. R&D Systems, Inc.: COMPANY SNAPSHOT TABLE 78. R&D Systems, Inc.: OPERATING SEGMENTS TABLE 79. Cole-Parmer Instrument Company LLC: COMPANY SNAPSHOT TABLE 80. Cole-Parmer Instrument Company LLC: OPERATING SEGMENTS List of Figures (20 Figures) Figure 1 Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Figure 4 Research Methodology: Hypothesis Building Figure 5 Product-Based Estimation Figure 6 Top 25 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2021 Figure 8 Import Data for Cell Counting, By Country, 2016–2021 (USD Thousand) Figure 9 Export Data for Cell Counting, By Country, 2016–2021 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11By End-Users, 2019 vs. 2025 (USD Million) Figure 12Share, By Product, 2019 vs. 2025 Figure 13 Geographical Snapshot of the Figure 14 Spectrophotometers to Witness Higher CAGR in for Product Segment during Forecast Period. Figure 15 Hospitals & Diagnostic Laboratories to Witness Higher CAGR in for End-User Segment during Forecast Period. Figure 16 North America Accounted for the Largest Share of the By Regional Basis, in 2019 Figure 17 Drivers, Restraints, Opportunities, and Challenges Figure 18 North America: Snapshot Figure 19 Asia Pacific: Snapshot Figure 20 Vendor Dive: Evaluation Overview